Vitamin C can be combined to saline or glucose solutions. Vascular pain during infusion is most likely caused by the osmolarity of the solution. The concentration of vitamin C per 100ml of glucose or saline solution should not exceed 10g (20ml). Concentrations below this level are safe. For example, for 20g of vitamin c, you should use at least 200ml of base solution. In other words, you can use 500ml of saline solution but not 100ml. In addition, sterile water for injection should not be used with vitamin C doses of 30g or higher. The reason is that injectable vitamin C is in the form of Na-ascorbic acid and adding a high dose of over 30g or 40g to 500ml of saline solution increases the amount of Na⁺ drastically, causing vascular rigidity or other Na⁺ related side effects. Adding appropriate doses of B-com or magnesium is also a good way to increase safety.

 

In healthy individuals, megadose IVC therapy can begin with lower vitamin C doses of 10g or 20g with great safety and excellent antioxidant action. Protocols for Megadose IVC 10g and 20g is as follows:

 

"Mega 10 = N/S 250ml, vitamin C 10g, B-com 0.5A, 10% Mg-2ml, Ca-2ml"

"Mega 20 = N/S 250ml, vitamin C 20g, B-com 0.5A, 10% Mg-3ml, Ca-3ml"

 

Once comfortable with megadose IVC techniques, I invite my colleagues to take interest in ultra megadose IVC for cancer patients. The National Cancer Institute (NCI) of the US introduces the benefits of vitamin C in cancer therapy on their website. Recently, Atsuo Yanagisawa (President of International Society for Orthomolecular Medicine) of Japan recently published a book titled Glutathione cures Parkinson’s disease. On page 125 of his book, he provides a table showing the clinical evidence of vitamin C used in anti-cancer therapy (Figure 4). 

Figure 4. Study centers of vitamin C cancer therapy research.

(Source: Atsuo Yanagisawa’s Glutathione cures Parkinson’s disease)

 

I would like to emphasize that I am not brushing aside the traditional cancer therapies by supporting vitamin C therapy. Neither am I intending to use vitamin C as a main treatment of cancer. A growing number of studies report that combining megadose IVC to traditional cancer helps reduce side effects such as cellular toxicity while increasing the efficacy of chemical therapy or radiotherapy. Therefore, we should continue to pay attention to the usefulness of megadose IVC in cancer management in primary care settings. Another benefit of megadose IVC is that it can be carried out by a primary physician near a patient’s home, thereby increasing the convenience and comfort for patients.

 

-To be continued